Search results for "INHALATION"

showing 10 items of 326 documents

Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma.

2006

The widespread use of inhaled corticosteroids (ICS) for the treatment of persistent asthma, although highly effective, may be associated with both systemic and local side effects. Systemic side effects of ICS have been extensively studied. In contrast, relatively few studies have been performed to specifically evaluate local side effects of ICS. These local side effects--including oropharyngeal candidiasis, dysphonia, pharyngitis, and cough--are generally viewed as minor complications of therapy. However, they can be clinically significant, affect patient quality of life, hinder compliance with therapy, and mask symptoms of more serious disease. Local side effects result from deposition of …

DrugAdultmedicine.medical_specialtyAllergymedicine.drug_classmedia_common.quotation_subjectImmunologyOropharynxCiclesonideOropharyngeal Candidiasischemistry.chemical_compoundAdrenal Cortex HormonesAdministration InhalationmedicineImmunology and AllergyHumansIntensive care medicineChildmedia_commonAsthmaVoice DisordersInhalationbusiness.industryCandidiasisPharyngitismedicine.diseasePharyngitisAsthmachemistryCoughAnesthesiaCorticosteroidmedicine.symptombusinessAllergy
researchProduct

Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (F…

2018

Introduction: FRI is a novel computational fluid dynamics (CFD)-based technique using formulation profile and patients lung CT scan to simulate aerosol deposition. Aims and objectives: To evaluate lung deposition of pressurized metered dose inhaler (pMDI) extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G Trimbow®) with pMDI extrafine BDP/FF (Foster®) pMDI and compared them with reference gamma scintigraphy data. Methods: FRI was used to assess, in silico, the deposition of pMDI combination products (BDP/FF/G and BDP/FF) in 20 moderate to severe COPD patients. FRI combined high-resolution lung CT scans of each patient with in silico computational flow simulati…

DrugInhalationLung depositionmedicine.diagnostic_testmedicine.drug_classCopd patientsbusiness.industrymedia_common.quotation_subjectBeclometasone dipropionaterespiratory systemScintigraphy030226 pharmacology & pharmacyMetered-dose inhaler03 medical and health sciences0302 clinical medicine030228 respiratory systemmedicineCorticosteroidNuclear medicinebusinessmedia_commonmedicine.drugAirway pharmacology and treatment
researchProduct

Aerosolized GLP-1 for Treatment of Diabetes Mellitus and Irritable Bowel Syndrome

2014

Diabetes is a global burden and the prevalence of the disease, in particular diabetes mellitus type 2 is rapidly increasing worldwide. After introduction of insulin into clinical therapy about 90 years ago a major number of pharmaceuticals has been developed for treatment of diabetes mellitus type 2. One of these, the incretin glucagon-like peptide 1 (GLP-1), like insulin, needs subcutaneous administration causing inconvenience to patients. However, administration of GLP-1 plays also a role for treatment of irritable bowel syndrome (IBS). To improve patient convenience inhaled insulin (Exubera®) was developed and approved but failed market acceptance some years ago. Recently, another inhala…

Drugendocrine systemmedicine.medical_specialtyInhalationbusiness.industrymedia_common.quotation_subjectInsulinmedicine.medical_treatmentdigestive oral and skin physiologyIncretinDiseasemedicine.diseaseGlucagon-like peptide-1Diabetes mellitusInternal medicinemedicinebusinesshormones hormone substitutes and hormone antagonistsIrritable bowel syndromemedia_common
researchProduct

Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

2016

Age represents an exclusion criterion in randomized clinical trials designed to test the efficacy and safety of inhaled drugs in asthma. As a consequence, data on efficacy and safety of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) combinations in elderly asthmatics are scanty. Older age is associated with an increased proportion of comorbid conditions; in addition, all organ functions undergo a process of senescence, thus reducing their ability to metabolize the agents. Overall, these age-associated conditions may variably, and often unpredictably, affect the metabolism and excretion of respiratory drugs. However, pharmacological treatment of asthma does not follow specifi…

Druglong-acting β2 agonistmedicine.medical_specialtyasthma treatmentmedia_common.quotation_subjectPopulationReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialPharmacokineticsInhaled corticosteroidlawmedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticseducationAdverse effectIntensive care medicineAsthmamedia_commoneducation.field_of_studyChemical Health and SafetyInhalationbusiness.industryaginglung functionGeneral Medicinemedicine.diseasecomorbidity030228 respiratory systemAnesthesiaPharmacodynamicslong-acting β2 agonistsinhaled corticosteroidsbusinessSafety ResearchTherapeutics and clinical risk management
researchProduct

Asthma Control: The Right Inhaler for the Right Patient

2015

Inhaled therapy is the cornerstone of asthma management in that it optimizes the delivery of the medication to the site of action. The effectiveness of inhaled therapy is affected by the correct choice of the device and proper inhalation technique. In fact, this influences the drug delivery and distribution along the bronchial tree, including the most peripheral airways. In this context, accumulating evidence supports the contribution of small airways in asthma, and these have become an important target of treatment. In reality, the “ideal inhaler” does not exist, and not all inhalers are the same. Advances in technology has highlighted these differences, and have led to the design of new d…

Drugmedicine.medical_specialtyChemistry Pharmaceuticaldevice asthmamedia_common.quotation_subjectContext (language use)ReviewPeripheral airwaysSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthma managementPatient Education as TopicAsthma controlAsthma controlAdministration InhalationmedicineHumansPharmacology (medical)Intensive care medicineAsthmamedia_commonMedicine(all)Inhalationbusiness.industryNebulizers and VaporizersInhalerInhalerGeneral Medicinemedicine.diseaseAsthmaLung functionAdherenceChronic DiseaseDrug deliveryPatient CompliancebusinessAdvances in Therapy
researchProduct

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

2020

Inhalation therapy allows conveying drugs directly into the airways. The devices used to administer inhaled drugs play a crucial role in the management of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). To ensure high bronchial deposition of the drug, a device should deliver a high proportion of fine particles, be easy to use, and provide constant and accurate doses of the active substance. Nowadays, four different types of inhalers are widely used: nebulizers, dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Nebulizers can be used by patients unable to use other inhalers. However, they require l…

Drugmedicine.medical_specialtyRespiratory TherapyRespimatmedia_common.quotation_subjectSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyMDI03 medical and health sciencesRoute of administrationPulmonary Disease Chronic Obstructive0302 clinical medicineAsthma COPD DPI MDI Nebulizer RespimatAdministration InhalationInternal MedicinemedicineCOPDHumans030212 general & internal medicineMetered Dose InhalersIntensive care medicineAsthmamedia_commonCOPDInhalationbusiness.industryInhalerNebulizers and VaporizersNebulizerEquipment Designmedicine.diseaseAsthma; COPD; DPI; MDI; Nebulizer; RespimatAsthmaRespimatDPINebulizerbusinessEuropean journal of internal medicine
researchProduct

Nanocarriers for respiratory diseases treatment: Recent advances and current challenges

2014

Pulmonary delivery of locally-acting drugs encapsulated in nanocarriers provides several advantages for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary diseases, cystic fibrosis, tuberculosis and lung cancer. These advantages include, among others, sustained drug delivery to the lungs, reduced therapeutic dose and improved patient compliance. The aim of this review is to give an updated overview on recent advances recorded in the last few years in this field as well as on the major challenges still existing and that remain to be overcome before any clinical application. After an outline on the cellular and extracellular barriers affecting drug delivery to…

Drugmedicine.medical_specialtymedia_common.quotation_subjectpulmonary deliveryAntitubercular AgentsMicrobial Sensitivity TestsGene deliveryPharmacologyCystic fibrosisTherapeutic indexDrug DiscoverymedicineAnimalsHumansTuberculosisIntensive care medicinemedia_commonDrug CarriersLungrespiratory diseasesbusiness.industryMycobacterium tuberculosisGeneral Medicinemedicine.diseaseinhalation of polymeric- and lipid-based nanocarriermedicine.anatomical_structurelung targetingTargeted drug deliveryDrug deliverymucus penetrationNanoparticlesNanocarriersbusinessDefense mechanism
researchProduct

Statistical tools and control of internal lubricant content of inhalation grade HPMC capsules during manufacture

2016

The internal lubricant content (ILC) of inhalation grade HPMC capsules is a key factor to ensure good powder release when the patient inhales a medicine from a dry powder inhaler (DPI). Powder release from capsules has been shown to be influenced by the ILC. The characteristics used to measure this are the emitted dose, fine particle fraction and mass median aerodynamic diameter. In addition the ILC level is critical for capsule shell manufacture because it is an essential part of the process that cannot work without it. An experiment has been applied to the manufacture of inhalation capsules with the required ILC. A full factorial model was used to identify the controlling factors and from…

Dry powder inhaler (DPI)Materials scienceChemistry PharmaceuticalPharmaceutical ScienceNanotechnologyCapsulesOleic Acids02 engineering and technology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineHypromellose DerivativesAdministration InhalationAerodynamic diameterHPMC capsulesLubricantskin and connective tissue diseasesLubricantsFactorial modelModels StatisticalInhalationDry Powder Inhalers021001 nanoscience & nanotechnologyHypromellose DerivativesDry-powder inhalerbody regionsAerosolizationInternal lubricantLinear models0210 nano-technologyMATEMATICA APLICADABiomedical engineeringParticle fraction
researchProduct

TGF-beta regulates airway responses via T cells.

2003

Abstract Allergic asthma is characterized by airway hyperreactivity, inflammation, and a Th2-type cytokine profile favoring IgE production. Beneficial effects of TGF-β and conflicting results regarding the role of Th1 cytokines have been reported from murine asthma models. In this study, we examined the T cell as a target cell of TGF-β-mediated immune regulation in a mouse model of asthma. We demonstrate that impairment of TGF-β signaling in T cells of transgenic mice expressing a dominant-negative TGF-β type II receptor leads to a decrease in airway reactivity in a non-Ag-dependent model. Increased serum levels of IFN-γ can be detected in these animals. In contrast, after injection of OVA …

Epitopes T-LymphocyteNitric Oxide Synthase Type IIImmunoglobulin EMiceAntibody SpecificityCell MovementT-Lymphocyte SubsetsTransforming Growth Factor betaImmunology and AllergyInterferon gammaLungInterleukin-13biologymedicine.diagnostic_testrespiratory systemImmunohistochemistrymedicine.anatomical_structureInterleukin 13Alum Compoundsmedicine.symptomBronchial HyperreactivityBronchoalveolar Lavage Fluidmedicine.drugGenetically modified mousemedicine.medical_specialtyOvalbuminT cellImmunologyCD2 AntigensInflammationMice Inbred StrainsMice TransgenicProtein Serine-Threonine KinasesInterferon-gammaInternal medicineAdministration InhalationmedicineAnimalsHumansAerosolsInflammationbusiness.industryReceptor Transforming Growth Factor-beta Type IITransforming growth factor betaImmunoglobulin ETh1 Cellsrespiratory tract diseasesEndocrinologyBronchoalveolar lavageImmunologybiology.proteinNitric Oxide SynthasebusinessReceptors Transforming Growth Factor betaJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

2021

Funder: Global Initiative for Asthma

ExacerbationRespiratory SystemINHALED CORTICOSTEROIDSCritical Care and Intensive Care MedicineAsthma managementSINGLE-INHALERDOUBLE-BLINDRisk Factorsimmune system diseasesAdrenal Cortex HormonesRELIEVER THERAPYFormoterol FumarateMedicine and Health SciencesImmunology and AllergyAnti-Asthmatic AgentsChild11 Medical and Health SciencesLung functionMILD PERSISTENT ASTHMAExecutive summaryBiologic therapiesCombined Modality TherapyLUNG-FUNCTIONChild PreschoolPractice Guidelines as TopicPerspectiveDisease ProgressionDrug Therapy Combinationmedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBUDESONIDE/FORMOTEROL MAINTENANCEAdolescentMild asthmaMEDLINEInhaled corticosteroidsCONTROLLED-TRIALSkills trainingGINA Strategy 2021: Executive SummaryBUDESONIDE-FORMOTEROLAdministration InhalationmedicineHumansasthma preventionIntensive care medicineSEVERE EXACERBATIONSAsthmaasthma diagnosisbusiness.industryPatient AcuityInfantasthmamedicine.diseaseAsthmarespiratory tract diseasesSelf Carewf_140Formoterolwf_100businessasthma management
researchProduct